A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Number and types of mutations in the primary tumor.
研究概览
简要总结
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
详细描述
The plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. The investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage IB and above non-small cell lung cancer or metastatic lung cancer
- •Age >18 years old
- •Willing and able to consent to study
- •No prior history of neoadjuvant therapy.
排除标准
- •Age <18 years old
- •Unable to provide consent
结局指标
主要结局
Number and types of mutations in the primary tumor.
时间窗: Within 1 year
Number and type of mutations detectable in the matched circulating tumor cell samples.
时间窗: Within 1 year
次要结局
- Concordance of mutations detected by either method.(Within 1 year)